Company (Symbol)

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

I. COMMENCED TRADING IN JUNE

INITIAL OFFERINGS

Cepheid (CPHD)1

4/7

6/21

5S

$6

25.5

UBS Warburg LLC Prudential Vector Healthcare Invemed Associates

$30.0

$26.6

Charles River Laboratories Corp. (NYSE: CRL)2

4/25

6/23

14S

$16

33.8

Donaldson, Lufkin & Jenrette (co-lead) Lehman Brothers (co-lead) ING Barings LLC SG Cowen Securities Corp. U.S. Bancorp Piper Jaffray Inc. DLJ direct Inc.

$224.0

$205.3

Dendreon Corp. (DNDN)3

3/8

6/16

4.5S

$10

20.9

Prudential Vector Healthcare SG Cowen Securities Corp. Pacific Growth Equities Inc.

$45.0

$40.4

MediGene AG (Germany; Neuer Markt: MDG)4

N/A

6/30

2.59S

EUR42 (US$40)

9.7

Bank Vontobel AG Morgan Stanley Dean Witter Commerzbank AG

EUR108.8 (US$103.6)

N/A

Modex Therapeutics Ltd. (Switzerland; SWX:MDXN)5

6/14

6/23

0.495S

CHF168 US$101.62

1.46

Bank J. Votobel & Co. AG

CHF83.2 (US$50.3)

N/A

Neurochem Inc. (Canada; TSE:NRM)6

5/10

6/13

3.88S

C$8.25 US$5.59

Loewen Ondaatje McCutcheon Canaccord Capital Corp.

C$32.0 (US$21.7)

C$30.1 (US$20.4)

Total: $474.6M

Number of IPOs year-to-date: 32

Number of IPOs in June: 6

Average value of June IPOs: $79.1M

Total raised in IPOs year-to-date: $2,975.8M

Average value: $93.0M

Notes:

1 The underwriters of Cepheid's offering have an overallotment option for an additional 750,000 shares.

2 The underwriters of Charles River's offering have an overallotment option for an additional 2.1M shares.

3 The underwriters of Dendreon's offering have an overallotment option for an additional 675,000 shares.

4 MediGene's offering was conducted in Germany. The underwriters have an overallotment option for an additional 400,000 shares.

5 Modex's offering was conducted in Switzerland. The underwriters have an overallotment option for an additional 675,000 shares.

6 Neurochem's offering was conducted in Canada. The underwriters have an overallotment option for an additional 581,818 shares.

FOLLOW-ON OFFERINGS

SignalGene Inc. (Canada; TSE:SGI)7

5/19

6/13

12.5

C$1.55 (US$1.05)

102.3

BMO Nesbitt Burns Inc. National Bank Financial Inc. Yorkton Securities Inc.

C$19.4 (US$13.2)

C$18.1 (US$12.3)

Total: $12.3M

Number of follow-on offerings in June: 1

Average value of June follow-ons: $12.3M

Number of follow-on offerings year-to-date: 36

Total raised in follow-ons year-to-date: $7,453.3M

Average value of follow-ons year-to-date: $207.0M

Notes:

7 SignalGene's offering was conducted in Canada. The underwriters have an overallotment option for 1.875M shares.

II. FILED AND PENDING

Company (Symbol)*

Date Filed

Shares/Units (M)

Price Range

Shares Out (M)**

Lead, Other Underwriters

Est. Value (M)

INITIAL OFFERINGS

3-Dimensional Pharmaceuticals Inc. (DDDP)1

5/23

N/A

N/A

N/A

Bear Stearns & Co. Chase H&Q U.S. Bancorp Piper Jaffray

$70.0

Applied Molecular Evolution Inc. (AMEV)2

5/12

3.75

$15-17

17.5

CIBC World Markets Corp. PaineWebber Inc. SG Cowen Securities Corp.

$60.0

Arena Pharmaceuticals Inc. (ARNA)3

4/28

5

$15-17

14.7

ING Barings LLC Prudential Vector Healthcare SG Cowen Securities Corp.

$80.0

Argonaut Technologies Inc. (AGNT)4

4/27

4

$13-15

12.4

UBS Warburg LLC ING Barings LLC SG Cowen Securities Corp.

$56.0

AtheroGenics Inc. (AGIX)5

2/25

N/A

N/A

N/A

SG Cowen Securities Corp. Chase H&Q Adams, Harkness & Hill A.G. Edwards & Sons Inc.

$100.0

Cellomics Inc. (CLMX)6

3/3

6S

$16-18

13.6

Prudential Vector Healthcare ING Barings LLC Dain Rauscher Wessels

$102.0

Ciphergen Biosystems Inc. (CIPH)7

3/20

N/A

N/A

N/A

SG Cowen Securities Corp. ING Barings LLC Warburg Dillon Read LLC

$86.3

Decode Genetics Inc. (Iceland; DCGN)8

3/8

8S

$14-18

32.7

Morgan Stanley Dean Witter Lehman Brothers

$128.0

Deltagen Inc. (DGEN)9

4/13

7S

$13-15

21.8

Salomon Smith Barney Robertson Stephens U.S. Bancorp Piper Jaffray

$98.0

Discovery Partners International Inc. (DPII)10

5/9

5S

$15-17

17.4

Chase H&Q (co-lead) Lehman Brothers (co-lead) Warburg Dillon Read LLC

$80.0

Durect Corp. (DRRX)11

4/20

N/A

N/A

N/A

Morgan Stanley Dean Witter Chase H&Q CIBC World Markets Corp.

$115.0

Dyax Corp. (DYAX)12

5/19

N/A

N/A

N/A

JP Morgan Securities Inc. Lehman Brothers Inc. Pacific Growth Equities Inc.

$75.0

Esperion Therapeutics (ESPR)13

2/24

N/A

N/A

N/A

Robertson Stephens (co-lead) Chase H&Q (co-lead) U.S. Bancorp Piper Jaffray

$138.0

Gemini Genomics plc (UK)14

6/23

12S

$12-14

N/A

SG Cowen Securities Corp. Chase H&Q

$78.0

Genaissance Pharmaceuticals Inc. (GNSC)15

4/20

6S

$11-13

15.6

Deutsche Banc Alex. Brown Inc. Bear Stearns & Co. Inc. Salomon Smith Barney Inc. Warburg Dillon Read LLC

$72.0

Genencor International Inc. (GCOR)16

5/8

7S

$16-18

51.9

Merrill Lynch Chase H&Q Credit Suisse First Boston Corp. Salomon Smith Barney Inc.

$119.0

Genometrix Inc. (GNMX)17

3/15

7S

$10-12

23.0

Lehman Brothers (co-lead) Chase H&Q (co-lead) Dain Rauscher Wessels Thomas Weisel Partners LLC Fidelity Capital Markets

$77.0

Genomica Corp. (GNOM)18

3/15

6S

$15-17

15.7

CIBC World Markets Dain Rauscher Wessels Prudential Vector Healthcare Stadtsparkasse Kvln

$96.0

Illumina Inc. (ILMN)19

4/3

5S

$9-11

25.5

Goldman Sachs & Co. Chase H&Q SG Cowen Securities Corp.

$50.0

Inspire Pharmaceuticals Inc. (ISPH)20

2/25

5.5S

$10-12

19

Bear, Stearns & Co. Inc. Deutsche Banc Alex. Brown U.S. Bancorp Piper Jaffray

$60.5

Introgen Therapeutics Inc. (INGN)21

2/17

N/A

N/A

10.3

SG Cowen Securities Corp. Prudential Securities Inc.

$92.0

Ista Pharmaceuticals Inc. (ISTA)22

4/5

N/A

N/A

N/A

CIBC World Markets Corp. ING Barings LLC Prudential Vector Healthcare

$86.25

Keryx Biopharmaceuticals Inc. (Israel; KERX)23

5/19

4.6

$10-12

14.2

Roth Capital Partners Inc. (U.S. lead) WestLB Panmure Ltd. (European lead)

$50.6

Kosan Biosciences Inc. (KOSN)24

3/31

N/A

N/A

N/A

Warburg Dillon Read LLC CIBC World Markets Prudential Vector Healthcare

$80.0

Large Scale Biology Corp. (LSBC)25

4/6

3.57

$20-22

11.9

J.P. Morgan & Co. Chase H&Q William Blair LLC & Co.

$75.0

MediChem Life Sciences Inc. (MCLS)26

6/16

N/A

N/A

N/A

UBS Warburg LLC Chase H&Q William Blair & Co.

$50.0

The Medicines Company (MDCO)27

5/19

5S

$14-16

23.2

J.P. Morgan & Co. Robertson Stephens CIBC World Markets

$75.0

NetGenics Inc. (NTGC)28

3/13

5.5S

$12

18.0

Chase H&Q Warburg Dillon Read LLC

$66.0

Pain Therapeutics Inc. (PTIE)29

3/4

5S

$11-13

20.9

Robertson Stephens CIBC World Markets Lazard Freres & Co. LLC

$60.0

Pharsight Corp. (PHST)30

4/17

3.75

$12-15

14.8

Donaldson, Lufkin & Jenrette Chase H&Q Wit Soundview DLJ Direct Inc.

$50.6

Regeneration Technologies Inc. (RTIX)31

4/27

5.7

$12-14

15.6

Banc of America Securities LLC Lehman Brothers Inc. Warburg Dillon Read LLC Stephens Inc.

$74.1

Rosetta Inpharmatics Inc. (RSTA)32

3/17

7S

$10-12

22.0

Lehman Brothers Lazard Freres & Co. LLC Prudential Vector Healthcare Fidelity Capital Markets

$77.0

Telik Inc. (TELK)33

4/3

5S

$9-11

16.1

Lehman Brothers
Chase H&Q
Legg Mason Wood Walker Inc.
UBS Warburg LLC
Fidelity Capital Markets

$50.0

Transgenomic Inc. (TBIO)34

3/10

4S

$12-14

13.3

Chase H&Q Bear, Stearns & Co. Dain Rauscher Wessels

$52.0

Variagenics Inc. (VGNX)35

3/29

5S

$11-13

17.3

Credit Suisse First Boston Chase H&Q SG Cowen Securities Corp.

$60.0

Versicor Inc. (VERS)36

3/22

N/A

N/A

N/A

Lehman Brothers Chase H&Q Pacific Growth Equities Inc. UBS Warburg LLC

$86.3

FOLLOW-ON OFFERINGS

AltaRex Corp. (TSE:AXO)37

4/24

N/A

N/A

55.7

HSBC Securities Roth Capital Partners Greenwich Global LP

N/A

AVI BioPharma Inc. (AVII)38

6/16

3S

$12

16.6

Paulson Investment Co. I-Bankers Securities Inc.

$36.0

III. WITHDRAWN OR POSTPONED

Signal Pharmaceuticals Inc. (SGNL)39

2/18

5S

$13-15

14.2

Robertson Stephens Chase H&Q CIBC World Markets

$70.0

Notes:

* Stock symbols for companies seeking to complete IPOs are proposed.

** Shares outstanding exclude new shares to be issued in the offering.

1 3-D's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $70M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

2 Applied Molecular's prospectus was amended 6/26/00. The estimated value of the IPO, $60M, is based on the sale of 3.75M shares at $16, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 562,500 shares.

3 Arena's prospectus was amended 6/22/00. The estimated value of the IPO, $80M, is based on the sale of 5M shares at $16, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 750,000 shares.

4 Argonaut's prospectus was amended 6/19/00. The estimated value of the IPO, $56M, is based on the sale of 4M shares at $14, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 600,000 shares.

5 AtheroGenics' prospectus was amended 3/6/00. The filing leaves blank the number of shares, price per share and shares outstanding. The estimated value of the IPO, $100M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

6 Cellomics' prospectus was amended 4/14/00. The estimated value of the IPO, $102M, is based on the sale of 6M shares at $17, the midpoint of the expected price range. The underwriters have an overallotment option for 900,000 shares.

7 Ciphergen's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $86.3M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

8 Decode's prospectus was amended 5/15/00. The estimated value of the IPO, $128M, is based on the sale of 8M shares at $16, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 1.2M shares.

9 Deltagen's prospectus was amended 6/15/00. The estimated value of the IPO, $98M, is based on the sale of 7M shares at $14 per share, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 1.05M shares.

10 Discovery Partners' prospectus was amended 6/16/00. The estimated value of the IPO, $80M, is based on the sale of 5M shares at $16, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 750,000 shares.

11 Durect's prospectus was amended 6/16/00. It leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $115M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

12 Dyax's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $75M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

13 Esperion's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $138M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

14 Gemini filed a form F-1 with the U.S. Securities and Exchange Commission to sell 12M ordinary shares in the form of American depositary shares. Each ADS represents two ordinary shares and is expected to price between $12 and $14. The estimated value of the IPO, $78M, is based on the sale of 6M ADSs at $13, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 900,000 ordinary shares.

15 Genaissance's prospectus was amended 7/3/00. The estimated value of the IPO, $72M, is based on the sale of 6M shares at $12, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 900,000 shares.

16 Genencor's prospectus was amended 6/30/00. The estimated value of the IPO, $119M, is based on the sale of 7M shares at $17, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 1.05M shares.

17 Genometrix's prospectus was amended 4/19/00, 5/2/00, 5/22/00 and 5/23/00. The estimated value of the IPO, $77M, is based on the sale of 7M shares at $11 per share, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 1.05M shares.

18 Genomica's prospectus was amended 3/16/00, 4/19/00 and 4/20/00. The estimated value of the IPO, $96M, is based on the sale of 6M shares at an assumed price of $16 per share. The underwriters have an overallotment option for an additional 900,000 shares.

19 Illumina's prospectus was amended 7/3/00. The estimated value of the IPO, $50M, is based on the sale of 5M shares at $10, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 750,000 shares.

20 Inspire's prospectus was amended 2/25/00 and 6/29/00. The estimated value of the IPO, $60.5M, is based on the sale of 5.5M shares at $11, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 825,000 shares.

21 Introgen's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $92M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

22 Ista's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $86.25M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

23 Keryx's prospectus was amended 6/30/00. The estimated value of the IPO, $50.6M, is based on the sale of 4.6M shares at $11, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 690,000 shares.

24 Kosan's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $80M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

25 Large Scale's prospectus was amended 6/29/00. The estimated value of the IPO, $75M, is based on the sale of 3.57M shares at $21, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 535,500 shares.

26 MediChem's prospectus leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $50M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

27 The Medicines Company's prospectus was amended 7/3/00. The estimated value of the IPO, $75M, is based on the sale of 5M shares at $15, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 750,000 shares.

28 The estimated value of NetGenics' IPO, $66M, is based on the sale of 5.5M shares at an assumed price of $12 per share. The underwriters have an overallotment option for an additional 825,000 shares.

29 Pain Therapeutics' prospectus was amended 5/11/00 and 6/20/00. The estimated value of the IPO, $60M, is based on the sale of 5M shares at $12, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 750,000 shares.

30 Pharsight's prospectus was amended 6/12/00. The estimated value of the IPO, $50.6M, is based on the sale of 3.75M shares at $13.50, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 562,500 shares.

31 Regeneration's prospectus was amended 5/15/00, 5/24/00 and 6/23/00. The estimated value of the IPO, $74.1M, is based on the sale of 5.7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 855,000 shares.

32 Rosetta's prospectus was amended 4/15/00, 5/9/00, 6/14/00 and 6/21/00. The estimated value of the IPO, $77M, is based on the sale of 7M shares at $11, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 1.05M shares.

33 Telik's prospectus was amended 7/3/00. The estimated value of the IPO, $50M, is based on the sale of 5M shares at $10, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 750,000 shares.

34 Transgenomic's prospectus was amended 5/7/00 and 6/27/00. The estimated value of the IPO, $52M, is based on the sale of 4M shares at an assumed price of $13 per share. The underwriters have an overallotment option for an additional 600,000 shares.

35 Variagenics' prospectus was amended 6/26/00. The estimated value of the IPO, $60M, is based on the sale of 5M shares at $12, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 750,000 shares.

36 Versicor's prospectus was amended 6/9/00. The filing leaves blank the number of shares, share price and number of shares outstanding. The estimated value of the IPO, $86.3M, is the proposed maximum aggregate offering price, which is used to calculate SEC filing fees.

37 AltaRex's prospectus leaves blank the number of shares to be offered, the price per share and the total amount the company is seeking in the offering.

38 The estimated value of AVI's offering, $36M, is based on the sale of 3M shares at the assumed price of $12. The underwriters have an overallotment option for an additional 450,000 shares.

39 Signal withdrew its offering prospectus 6/30/00 and announced plans to merge with Celgene Corp. (CELG).

No Comments